echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > New combination therapy could safely and effectively treat advanced prostate cancer

    New combination therapy could safely and effectively treat advanced prostate cancer

    • Last Update: 2020-06-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Prostate cancer is the most common cancer in U.Smen except skin cancerAccording to the American Cancer Society, about 175,000 new prostate cancer patients are diagnosed each year in the United States, and more than 315,000 men die from prostate cancer:Emmett L, Crumbaker M, Nguyen A, et al ,(mCRPC)。 Trials of targeted radionuclide therapy 177Lu PSMA 617 have been shown to be safe and effective in some men; Based on these trials, the researchers paired 177Lu PSMA 617 with the tumor-specific radiation sensitization agent idronoxil (NOX66) to assess the response of patients with severe mCRPCPhase I/II trials included 16 progressive mCRPC patients who had previously been treatedAll men received 6 doses of 177Lu PSMA 617 every 6 weeksHalf of patients (queue 1) received 400mg of additional treatment per day for 10 daysFollowing the safety data review, the remaining patients (queue 2) received 800 mg of additional treatment per day for NOX66The researchers found that nearly 70 percent of patients had reduced PSA levels by more than 50 percent after joint treatment (62.5 percent in group 1 and 75 percent in group 2)In addition, 31% of patients reported side effects such as fatigue and pneumonia (37.5% in queue 1 and 12.5% in queue 2)"Preliminary results from the dose upgrade study at this stage show that the combination is targeted and well tolerated, with no increase in toxicity of 177Lu PSMA 617, and is effective for male patients who have received various treatments." Dr Louise Emmett, associate professor at the University of New South Wales in Sydney, saidshe continued: "We are now in the second phase of the dose expansion experiment to further assess toxicity and efficacyThis provides a very important possibility for co-therapeutic effects of joint tumor-targeted therapy drugs without increasing side effects"
    Reference: New combination therapy sage as safe and an effective for prostate cancer
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.